Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
| ▸ | PGR | P06401 | 4/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | SHBG | P04278 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL6 | P05231 | 1/20 | 0.59 |
| ▸ | GLUL | P15104 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249836 | 0.99 | HIF1A (0.64) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL14931695 | 0.99 | HIF1A (0.64) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL1301994 | 0.97 | HIF1A (0.62) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL1535104 | 0.97 | HIF1A (0.63) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL27571456 | 0.96 | HIF1A (0.61) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL27941428 | 0.96 | HIF1A (0.61) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL141828 | 0.96 | HIF1A (0.62) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL28809123 | 0.96 | HIF1A (0.66) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL41085 | 0.95 | HIF1A (0.63) | HIF1AHSD17B10NR3C1CYP2C19PGR | |
| SCHEMBL4450350 | 0.95 | HIF1A (0.61) | HIF1AHSD17B10NR3C1CYP2C19PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-110096710-B | Article analysis and self-demonstration method | 董云鹏 | 2022-12-30 | — | — | CN | disclosed |
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| CN-113286778-A | Panamide analogs | MMV疟疾药物投资公司 | 2021-08-20 | — | — | CN | disclosed |
| EP-3810133-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | Neuropore Therapies, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112584874-A | Compositions and methods for treating leber's hereditary optic neuropathy | 武汉纽福斯生物科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112512523-A | Methods of treating conditions associated with neurodegenerative disorders using inhibitors of OAT3 | 神经孔疗法股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-2842545-B1 | METHOD FOR PRODUCING AN AQUEOUS DISPERSION OF DRUG NANOPARTICLES AND USE THEREOF | UNIV OSAKA (JP) | 2020-02-12 | — | — | EP | disclosed |
| CN-106924738-B | The pharmaceutical composition for preventing lemostenosis | 北京大学第三医院 | 2019-12-03 | — | — | CN | disclosed |
| CN-110214150-A | Combination therapy of chimeric antigen receptor and PD-1 inhibitor | 诺华股份有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-105820203-B | The preparation method of hydrocortisone acetate | 湖南成大生物科技有限公司 | 2017-08-08 | — | — | CN | disclosed |
| CN-106924738-A | Prevent the drug regimen of lemostenosis | 北京大学第三医院 | 2017-07-07 | — | — | CN | disclosed |
| CN-104030987-B | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | 默克雪兰诺有限公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20150087624-A1 | METHOD FOR PRODUCING AN AQUEOUS DISPERSION OF DRUG NANOPARTICLES AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2015-03-26 | — | — | US | disclosed |
| EP-2842545-A1 | METHOD FOR PRODUCING AN AQUEOUS DISPERSION OF DRUG NANOPARTICLES AND USE THEREOF | Osaka University (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-101137379-B | Cxcr4 antagonists for the treatment of HIV infection | UNIV EMORY | 2015-02-11 | — | — | CN | disclosed |
| CN-101282761-A | Benzimidazole derivatives as SIRTUIN modulators | SIRTRIS PHARMACEUTICALS INC (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101137379-A | Cxcr4 antagonists for the treatment of HIV infection | UNIV EMORY (US) | 2008-03-05 | — | — | CN | disclosed |
| US-20060140991-A1 | Pharmaceutical preparations having an improved solubility | AJINOMOTO CO. INC (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1661556-A1 | MEDICINAL PREPARATION HAVING IMPROVED DISSOLUTION PROPERTIES | Ajinomoto Co., Inc. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | OAT, CLN6, SLC2A3 | HIF1A 2469/4885HSD17B10 687/4885NR3C1 1761/4885 |
| US-20060140991-A1 | Pharmaceutical preparations having an improved solubility | SI, LSS, PDE8B | HIF1A 2142/4885HSD17B10 2433/4885NR3C1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.